DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine

Alessia Stornetta, Maike Zimmermann, George D. Cimino, Paul Henderson, Shana J. Sturla

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Biomarker-driven drug selection plays a central role in cancer drug discovery and development, and in diagnostic strategies to improve the use of traditional chemotherapeutic drugs. DNA-modifying anticancer drugs are still used as first line medication, but drawbacks such as resistance and side effects remain an issue. Monitoring the formation and level of DNA modifications induced by anticancer drugs is a potential strategy for stratifying patients and predicting drug efficacy. In this perspective, preclinical and clinical data concerning the relationship between drug-induced DNA adducts and biological response for platinum drugs and combination therapies, nitrogen mustards and half-mustards, hypoxia-activated drugs, reductase-activated drugs, and minor groove binding agents are presented and discussed. Aspects including measurement strategies, identification of adducts, and biological factors that influence the predictive relationship between DNA modification and biological response are addressed. A positive correlation between DNA adduct levels and response was observed for the majority of the studies, demonstrating the high potential of using DNA adducts from anticancer drugs as mechanism-based biomarkers of susceptibility, especially as bioanalysis approaches with higher sensitivity and throughput emerge.

Original languageEnglish (US)
Pages (from-to)388-409
Number of pages22
JournalChemical Research in Toxicology
Volume30
Issue number1
DOIs
StatePublished - Jan 17 2017

Fingerprint

Precision Medicine
DNA Adducts
Medicine
Pharmaceutical Preparations
Biomarkers
DNA
Mechlorethamine
Mustard Plant
Biological Factors
Drug Combinations
Drug Discovery
Combination Drug Therapy
Platinum
Oxidoreductases
Throughput
Monitoring

ASJC Scopus subject areas

  • Toxicology

Cite this

DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. / Stornetta, Alessia; Zimmermann, Maike; Cimino, George D.; Henderson, Paul; Sturla, Shana J.

In: Chemical Research in Toxicology, Vol. 30, No. 1, 17.01.2017, p. 388-409.

Research output: Contribution to journalArticle

Stornetta, Alessia ; Zimmermann, Maike ; Cimino, George D. ; Henderson, Paul ; Sturla, Shana J. / DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. In: Chemical Research in Toxicology. 2017 ; Vol. 30, No. 1. pp. 388-409.
@article{1eff612ea82047f9ab6482df743c3223,
title = "DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine",
abstract = "Biomarker-driven drug selection plays a central role in cancer drug discovery and development, and in diagnostic strategies to improve the use of traditional chemotherapeutic drugs. DNA-modifying anticancer drugs are still used as first line medication, but drawbacks such as resistance and side effects remain an issue. Monitoring the formation and level of DNA modifications induced by anticancer drugs is a potential strategy for stratifying patients and predicting drug efficacy. In this perspective, preclinical and clinical data concerning the relationship between drug-induced DNA adducts and biological response for platinum drugs and combination therapies, nitrogen mustards and half-mustards, hypoxia-activated drugs, reductase-activated drugs, and minor groove binding agents are presented and discussed. Aspects including measurement strategies, identification of adducts, and biological factors that influence the predictive relationship between DNA modification and biological response are addressed. A positive correlation between DNA adduct levels and response was observed for the majority of the studies, demonstrating the high potential of using DNA adducts from anticancer drugs as mechanism-based biomarkers of susceptibility, especially as bioanalysis approaches with higher sensitivity and throughput emerge.",
author = "Alessia Stornetta and Maike Zimmermann and Cimino, {George D.} and Paul Henderson and Sturla, {Shana J.}",
year = "2017",
month = "1",
day = "17",
doi = "10.1021/acs.chemrestox.6b00380",
language = "English (US)",
volume = "30",
pages = "388--409",
journal = "Chemical Research in Toxicology",
issn = "0893-228X",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine

AU - Stornetta, Alessia

AU - Zimmermann, Maike

AU - Cimino, George D.

AU - Henderson, Paul

AU - Sturla, Shana J.

PY - 2017/1/17

Y1 - 2017/1/17

N2 - Biomarker-driven drug selection plays a central role in cancer drug discovery and development, and in diagnostic strategies to improve the use of traditional chemotherapeutic drugs. DNA-modifying anticancer drugs are still used as first line medication, but drawbacks such as resistance and side effects remain an issue. Monitoring the formation and level of DNA modifications induced by anticancer drugs is a potential strategy for stratifying patients and predicting drug efficacy. In this perspective, preclinical and clinical data concerning the relationship between drug-induced DNA adducts and biological response for platinum drugs and combination therapies, nitrogen mustards and half-mustards, hypoxia-activated drugs, reductase-activated drugs, and minor groove binding agents are presented and discussed. Aspects including measurement strategies, identification of adducts, and biological factors that influence the predictive relationship between DNA modification and biological response are addressed. A positive correlation between DNA adduct levels and response was observed for the majority of the studies, demonstrating the high potential of using DNA adducts from anticancer drugs as mechanism-based biomarkers of susceptibility, especially as bioanalysis approaches with higher sensitivity and throughput emerge.

AB - Biomarker-driven drug selection plays a central role in cancer drug discovery and development, and in diagnostic strategies to improve the use of traditional chemotherapeutic drugs. DNA-modifying anticancer drugs are still used as first line medication, but drawbacks such as resistance and side effects remain an issue. Monitoring the formation and level of DNA modifications induced by anticancer drugs is a potential strategy for stratifying patients and predicting drug efficacy. In this perspective, preclinical and clinical data concerning the relationship between drug-induced DNA adducts and biological response for platinum drugs and combination therapies, nitrogen mustards and half-mustards, hypoxia-activated drugs, reductase-activated drugs, and minor groove binding agents are presented and discussed. Aspects including measurement strategies, identification of adducts, and biological factors that influence the predictive relationship between DNA modification and biological response are addressed. A positive correlation between DNA adduct levels and response was observed for the majority of the studies, demonstrating the high potential of using DNA adducts from anticancer drugs as mechanism-based biomarkers of susceptibility, especially as bioanalysis approaches with higher sensitivity and throughput emerge.

UR - http://www.scopus.com/inward/record.url?scp=85015139223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015139223&partnerID=8YFLogxK

U2 - 10.1021/acs.chemrestox.6b00380

DO - 10.1021/acs.chemrestox.6b00380

M3 - Article

C2 - 27936622

AN - SCOPUS:85015139223

VL - 30

SP - 388

EP - 409

JO - Chemical Research in Toxicology

JF - Chemical Research in Toxicology

SN - 0893-228X

IS - 1

ER -